[Drugs and hepatitis B virus reactivation]

Area of Science:

• Hepatology
• Pharmacology
• Immunology

Background:

• Drug-induced hepatitis B virus reactivation (HBV-R) is a significant clinical concern.
• Various medications can precipitate HBV-R, impacting patient health and treatment continuity.

Purpose of the Study:

• To review the definition, harms, risk factors, and mechanisms of drug-induced HBV-R.
• To outline early identification and intervention strategies for HBV-R.
• To emphasize the need for further research into HBV-R mechanisms.

Main Methods:

• Literature review of HBV-R definition, harms, risk drugs, mechanisms, and interventions.
• Analysis of factors influencing HBV-R.
• Synthesis of current knowledge on HBV-R management.

Main Results:

• Multiple drug classes, including chemotherapy, immunotherapy, and direct-acting antivirals, can induce HBV-R.
• HBV-R mechanisms involve altering host immunity or activating HBV transcription.
• HBV-R can lead to severe liver damage and treatment interruption, affecting prognosis.

Conclusions:

• Precise identification of risk drugs, monitoring influencing factors, and preventive anti-HBV regimens can reduce HBV-R incidence.
• Clinical physicians must focus on early HBV-R identification and intervention.
• In-depth research on host-HBV-risk factor interactions is crucial for improved risk prediction and early intervention targets.